Cancer Bivision Pharma reports new cyclic peptides targeting FAP Feb. 11, 2026 Bivision Pharmaceuticals (Shanghai) Co. Ltd. has identified cyclic peptides targeting fibroblast activating protein α (FAP) reported to be useful for the treatment of cancer.Read More
Diagnostics Bivision Pharmaceuticals patents new radiolabeled conjugates Nov. 7, 2025 Bivision Pharmaceuticals (Shanghai) Co. Ltd. has disclosed peptide-drug conjugates reported to be useful for diagnosis and treatment of fibrosarcoma.Read More
